Recombinant activated factor VII (rFVIIa/NovoSeven®) in intractable haemorrhage: use of a clinical scoring system to predict outcome

• DOI: 10.1111/j.1423-0410.2005.00711.x
• Publication Date: 2005-11-07T14:23:57Z
• Authors: T. T. Biss; J. P. Hanley
• Keywords: Factor VIIa

Recombinant activated factor VII (rFVIIa/NovoSeven) has been advocated in the treatment of life-threatening haemorrhage, but appropriate clinical indications remain uncertain. The aim this study was to detect factors predictive outcome and incorporate them into a prognostically significant scoring system.Thirty-six patients received rFVIIa for uncontrolled surgical, traumatic or obstetric bleeding Northern Region UK over 45-month period. Clinical, laboratory data were examined. Characteristics survivor non-survivor groups compared. A prognostic system evaluated retrospectively according presence coagulopathy, renal impairment, hypothermia, greater than 10 units red cell transfusion, advanced age indication, with allocated low, intermediate high-risk groups.Clinical response occurred 26 (72%) reduction prothrombin time blood product requirements. Death 19 (53%). Four (11%) suffered thrombotic events. Survivors younger non-survivors less likely have impairment hypothermia at administration. more had an initial terms immediate haemorrhage. Non-survivors transfused number prior Survival varied score; low-risk survival rate 85%, intermediate-risk 50% 18%.FVIIa role cessation may not improve survival. Use help predict outcome.